role of ultraviolet B, interleukin-1alpha, interleukin-1beta, endothelin-1 and tumour necrosis factor-alpha. Br JDermatol. 1998;139:216-24. [ Links ]57. Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, Yim H, et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002;146:228-37. [ Links ]58. Bohm M, Metze D, Schulte U, Becher E, Luger TA, Brzoska T. Detection of melanocortin-1 receptor antigenicity on human skin cells in culture and in situ. Exp Dermatol. 1999;8:453-61. [ Links ]59. Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MC Jr. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698-710. [ Links ]60. Johnston GA, Sviland L, McLelland J. Melasma of the arms associated with hormone replacement therapy. Br J Dermatol. 1998;139:932. [ Links ]61. Piamphongsant T. Treatment of melasma: a review with personal experience. Int J Dermatol. 1998;3:897-903. [ Links ]62. Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453-7. [ Links ]63. Ponzio HAS. Contribuicao a classificacao clinica e histopatologica dos melasmas [dissertacao]. Porto Alegre: UFRGS; 1995. p. 157. [ Links ]64. Guevara IL, Pandya AG. Melasma treated with hydroquinone, tretinoin, and a fluorinated steroid. Int J Dermatol. 2001;40:212-5. [ Links ]65. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572-7. [ Links ]66. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida AR, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2006;156 Suppl 1:13-20. [ Links ]67. Dominguez AR, Balkrishnan R, Ellzey AR, Pandya AG. Melasma in Latina patients: cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish language. J Am Acad Dermatol. 2006;55:59-66. [ Links ]68. Ponzio HAS, Cruz MF. Acuracia do exame sob a lampada de Wood na classificacao dos cloasmas. An Bras Dermatol. 1993;68:325-8. [ Links ]69. Wolf R, Wolf D, Tamir A, Politi Y. Melasma: a mask of stress. Br J Dermatol. 1991; 125: 192-3. [ Links ]70. Robins AH. Melanosis after prolonged chlorpromazine therapy. S Afr Med J. 1975;49:1521-4. [ Links ]71. Sacre RC, Fernandes NC, Vaisman M, Tendrich M. Melasma idiopatico: avaliacao das funcoes tireoidiana, prolactinica e gonadal feminina. An Bras Dermatol. 1996;71:195-8. [ Links ]72. Scheinfeld NS. Melasma. Skinmed. 2007;6:35-7. [ Links ]73. Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J Cosmet Dermatol. 2007;6:195-202. [ Links ]74. Grimes P, Nordlund JJ, Pandya AG, Taylor S, Rendon M, Ortonne JP. Increasing our understanding of pigmentary disorders. J Am Acad Dermatol. 2006;54:S255-61. [ Links ]75. Pandya A, Berneburg M, Ortonne JP, Picardo M. Guidelines for clinical trials in melasma. Pigmentation Disorders Academy. Br J Dermatol. 2006;156 Suppl 1: 21-8. [ Links ]76. Hexsel D, Arellano I, Rendon M. Ethnic considerations in the treatment of Hispanic and Latin-American patients with hyperpigmentation. Br J Dermatol. 2006; 156 Suppl:7-12. [ Links ]77. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment